Company / Operating Income
Matinas BioPharma Holdings, Inc. Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$24.6M
FY2024
5-year range
-$24.7M / -$24.2M
FY2020-FY2024
Trend
-0.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$25M in FY2022 to -$8M in FY2016.
Based on SEC 10-K filings.
-$25M in FY2024.
Remained stable around -$25M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating income decreased 0.0% year-over-year.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$24.6M | -0.0% |
| FY2023 | -$24.6M | +0.6% |
| FY2022 | -$24.7M | +0.0% |
| FY2021 | -$24.7M | -2.2% |
| FY2020 | -$24.2M | -65.3% |
| FY2019 | -$14.6M | +11.2% |
| FY2018 | -$16.5M | -66.5% |
| FY2017 | -$9.9M | -20.0% |
| FY2016 | -$8.3M | +16.7% |
| FY2015 | -$9.9M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026